Inhalerx Ltd (irx) Logo

Inhalerx Ltd (IRX)

___:___ · Healthcare

IRX Chart


IRX's Principal Activity is the developing and commercializing medical diagnostic and monitoring technology and digitally enabled drug delivery systems.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -7.57%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,899 of 2,413
Sector Rank 170 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies HGV / AJJ / BPH
EPS -$0.007
DPS $0.00
Book Value Per Share $0.02

Broker Consensus

IRX is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

InhaleRx Limited (IRX, formerly Lifespot Health Ltd ) focus on medical inhalation devices for the delivery of prescribed medicines.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Sydney NSW 2000
Registry Computershare
Auditor HLB Mann Judd (VIC) Partnership
Date Listed 11 Jan 2017

Upcoming Calendar (Forecasted)

Date Event
31/08/2022 Report (Interim)
30/01/2023 Report (Quarterly)
27/02/2023 Report (Prelim)
30/03/2023 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Sean Williams Non-Executive Chairman,Non-Executive Director Jul 2021

Mr Sean Williams

Non-Executive Chairman,Non-Executive Director

Mr Williams has over 30 years experience in senior executive and finance roles across the pharmaceutical, healthcare, investment management and supply chain sectors. Having commenced his career with an international accounting firm, Sean has held a number of senior roles including General Manager, Finance for Symbion Pharmacy (Australia's largest pharmaceutical wholesaler). He also headed up Symbion's market leading hospital pharmacy and dental divisions and was responsible for Independent Pharmacy Solutions (a short-line wholesale business). Sean has worked as an investment director in private equity and as a senior executive in private equity backed ventures.

Dr Andrew Saich Non-Executive Director Jul 2021

Dr Andrew Saich

Non-Executive Director

Dr Saich has worked in both large and small pharmaceutical companies. He has been involved in pharmaceutical Industry for over 20 years and has gained experience of international management, medicines commercialization and pharmaceutical R&D. Andrew is currently Chief Medical Officer of Return Health, a US based biotech company developing novel psychedelic treatments for patients with dementia and a co-founder of Diligenc. Capital, a cannabinoid prescription medicines investment group and Diligenc. Pathways, a consultancy comprising senior cannabinoid specialists from the ex-GW Pharmaceuticals team. In previous roles, Andrew was the European Medical Director responsible for establishing the Intercept Pharmaceuticals international medical and commercial organization as the company expanded from its New York corporate headquarters into thirteen countries across Europe. In 2016 Andrew created and led the GW Pharmaceuticals International Medical organization in preparation for the launch of Epidyolex (cannabidiol) for the treatment of rare and debilitating drug-resistant epilepsies. GW Pharmaceuticals (recently acquired by Jazz Pharmaceuticals) was the world leader in the development of cannabinoid medicines and Andrew was a senior member of the international management team, the strategic launch team, the Clinical Development Committee and the Corporate Drug Safety team. Andrew networks with politicians, governmental organizations and pharmaceutical regulators during his time at GW and lead both the global investigator initiated studies program and the global compassionate use program. Post GW Pharmaceuticals Andrew became Chief Medical Officer of Senzer Pharmaceuticals with responsibility for a clinical development program utilizing inhaled cannabinoids.

Mr Darryl Davies Executive Director Jul 2021

Mr Darryl Davies

Executive Director

Mr Davies has over 15 years' experience in psychology, healthcare and harm minimisation. Darryl has a background in harm minimisation, substance misuse treatment and social work, he then founded a wellness device start-up before entering the medicinal cannabis industry in 2017. Darryl co-founded private medicinal cannabis service provider, Cannvalate Pty Ltd. Darryl has global industry relationships and is nominated Australian Director of Canadian manufacturing leader, The Valens Company (NASDAQ:VLNS). He also sits on the Board of Directors for New Zealand cannabis company, Greenfern Industries Limited (NZX:GFI).

Ms Elizabeth Spooner Joint Company Secretary Jul 2021
Ms Nova Taylor Joint Company Secretary Jan 2021

Director Transactions

IRX directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
01/12/21 Sean Williams Buy +200,000 $0.095 $18,917 On-market trade
11/10/21 Darryl Davies Buy +305,248 $0.105 $32,051 On-market trade

Director Interests

The current holdings of IRX directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Darryl Davies 30/12/2021 N/A 33,524,924 N/A N/A
Sean Williams 30/12/2021 200,000 N/A N/A N/A
Andrew Saich 20/07/2021 0 N/A N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Mar 16, 2022.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Cannvalate Pty Ltd 33,524,924 19.90%
10 Bolivianos Pty Ltd 17,554,561 10.42%
M I D Wealth Pty Ltd 16,375,000 9.72%
Ela Capital Inc 11,329,573 6.73%
Pyxis Holdings Pty Ltd 10,683,475 6.34%
BNP Paribas Nominees Pty Ltd Acf Clearstream 5,466,380 3.24%
BNP Paribas Nominees Pty Ltd Cibc World Markets Inc (Drp) 4,163,438 2.47%
Superhero Nominees Pty Ltd (Client A/C) 3,978,377 2.36%
Mr Niv Dagan 2,682,013 1.59%
Dr David James Walland 2,005,262 1.19%
Apertus Capital Pty Ltd 2,000,000 1.19%
Mr Piper Belesprit Madison 1,800,038 1.07%
BNP Paribas Noms Pty Ltd (Drp) 1,691,802 1.00%
Mr Sean Christopher Reeves 1,672,318 0.99%
Mr Peter Steinmetz 1,500,000 0.89%
Nevertity Holdings Pty Ltd (J Isac Family A/C) 1,387,476 0.82%
Mr Shawn Yapp 1,360,000 0.81%
HSBC Custody Nominees (Australia) Limited 1,337,193 0.79%
Mr Noel Russell Cameron &Dr Belinda Caroline Goad (Noel Cameron Super Fund A/C) 1,321,920 0.78%
Sacco Developments Australia Pty Limited (The Sacco Family A/C) 1,150,000 0.68%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 31 95 143 249 132 650

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Niv Dagan 16/03/2022 19,172,302 11.38
Cannvalate Pty Ltd 16/03/2022 33,524,924 19.90
M I D Wealth Pty Ltd 16/03/2022 13,100,000 7.78
Ela Capital Inc 16/03/2022 14,515,743 8.62
Pyxis Holdings Pty Ltd 16/03/2022 8,909,441 5.29

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
17-12-21 Niv Dagan 4,271,022 8.85 11.38
11-10-21 Cannvalate Pty Ltd 3,335,302 19.21 19.90
18-08-21 Niv Dagan 5,283,082 7.14 8.85

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
IRX Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.